Results 11 to 20 of about 213,634 (311)

Hypertension in COVID-19, A Risk Factor for Infection or A Late Consequence? [PDF]

Cell Journal, 2022
There are a lot of data about the correlation of SARS-CoV-2 infection and hypertension (HTN), but most of themare in the increased risk of morbidity and mortality in patients with HTN. SARS-CoV-2 can interfere with host cellsthrough the renin-angiotensin
Maryam Barekat, Mohammad Amin Shahrbaf, Kosar Rahi, Massoud Vosough   +3 more
doaj   +1 more source

The angiotensin II type 2 receptor in the brain [PDF]

Journal of the Renin-Angiotensin-Aldosterone System, 2009
Recent clinical studies indicate that blockade of the renin-angiotensin system is important to prevent stroke, and accumulating results of basic research also indicate the possible involvement of the central renin-angiotensin system in ischaemic brain damage and cognition.
Masatsugu, Horiuchi, Masaki, Mogi, Masaru, Iwai   +2 more
openaire   +2 more sources

The effect of aerobic exercise on the function of the local renin-angiotensin system and gluconeogenesis pathway in the liver tissue of type 2 diabetic rats [PDF]

مجله علوم پزشکی فیض (پیوسته), 2023
Background and Aim: One of the important and effective physiological systems in the pathogenesis of type 2 diabetes is the local renin-angiotensin system. The aim of the current study was to determine the effect of aerobic exercise on the function of the
Mohadeseh Shojaei, Fatemeh Kazeminasab, Mohammadjavad Pourvaghar   +2 more
doaj   +2 more sources

Angiotensin-(1-7) and angiotensin-(1-9): function in cardiac and vascular remodeling [PDF]

, 2014
The renin angiotensin system (RAS) is integral to cardiovascular physiology, however, dysregulation of this system largely contributes to the pathophysiology of cardiovascular disease (CVD).
Akishita, Barroso, Booz, Bosnyak, Bosnyak, Brosnihan, Bruneval, Bryan, Calo, Campbell, Caroline Fattah, Castro, Chappell, Chappell, Chen, Christopher M. Loughrey, Clare A. McKinney, Clarke, Costa, Crackower, Cushman, De Mello, Dias-Peixoto, Domeier, Dong, Donoghue, Donoghue, Drummer, Faria-Silva, Ferreira, Ferreira, Ferreira, Ferreira, Flores-Munoz, Flores-Munoz, Fomovsky, Fraga-Silva, Fraga-Silva, Freeman, Galis, Gava, Gembardt, Gomes, Graeme Milligan, Grobe, Gusev, Hanke, Hannan, Harmer, Heitsch, Horiguchi, Horiuchi, Hunyady, Inaba, Iwata, Jackman, Jaiswal, Jarajapu, Kaminska, Kassiri, Katada, Kokkonen, Kramkowski, Langeveld, Lautner, Liao, Libby, Liu, Loot, Lovren, Masson, McCollum, Mehta, Mercure, Miura, Mogielnicki, Nakajima, Newby, Ng, Nouet, Ocaranza, Ocaranza, Ocaranza, Patel, Patel, Qi, Ray, Rice, Rodgers, Rodrigues-Machado, Ross, Rowe, Sampaio, Sampaio, Santos, Santos, Schultz Jel, Selvetella, Shah, Sheng-Long, Singh, Sluimer, Stegbauer, Strawn, Stuart A. Nicklin, Tallant, Tesanovic, Tipnis, Turner, Uekama, Varagic, Vickers, Vilas-Boas, Walters, Wang, Weber, West, Wiemer, Yamada, Yang, Zeng, Zhang, Zhao, Zhong   +123 more
core   +1 more source

The Angiotensin II Type 2 Receptor for Pain Control [PDF]

Cell, 2014
All well-known deleterious effects of angiotensin (Ang) II, including vasoconstriction, inflammation, water and salt retention, and vascular remodeling, are mediated via its type 1 (AT1) receptor. This explains why AT1 receptor blockers (ARBs) and inhibitors of Ang II synthesis, such as ACE inhibitors and renin inhibitors, are beneficial for ...
Danser, Jan, Anand, P
openaire   +3 more sources

Angiotensin II type 1 and type 2 receptor expression in circulating monocytes of diabetic and hypercholesterolemic patients over 3-month rosuvastatin treatment

Cardiovascular Diabetology, 2012
Background In diabetes, a variety of pro-inflammatory cellular changes has been found in various cell types, including monocytes which are known to be involved in all the phases of atherogenesis.
Marino Franca, Maresca Andrea Maria, Cosentino Marco, Castiglioni Luana, Rasini Emanuela, Mongiardi Christian, Maio Ramona C, Legnaro Massimiliano, Schembri Laura, Dentali Francesco, Grandi Anna Maria, Guasti Luigina   +11 more
doaj   +1 more source

Angiotensin II Type 2 Receptor Blockade Increases Bone Mass [PDF]

Journal of Biological Chemistry, 2009
Renin angiotensin system (RAS) regulates circulating blood volume and blood pressure systemically, whereas RAS also plays a role in the local milieu. Previous in vitro studies suggested that RAS may be involved in the regulation of bone cells. However, it was not known whether molecules involved in RAS are present in bone in vivo.
Yayoi, Izu, Fumitaka, Mizoguchi, Aya, Kawamata, Tadayoshi, Hayata, Testuya, Nakamoto, Kazuhisa, Nakashima, Tadashi, Inagami, Yoichi, Ezura, Masaki, Noda   +8 more
openaire   +3 more sources

Immunohistochemical expression of intrarenal renin angiotensin system components in response to tempol in rats fed a high salt diet [PDF]

, 2017
AIM:To determine the effect of tempol in normal rats fed high salt on arterial pressure and the balance between antagonist components of the renal renin-angiotensin system.METHODS:Sprague-Dawley rats were fed with 8% NaCl high-salt (HS) or 0.4% NaCl ...
Cao, Gabriel Fernando, Choi, Marcelo Roberto, Della Penna, Silvana Lorena, Fernandez, Belisario Enrique, Gorzalczany, Susana Beatriz, Kouyoumdzian, Nicolás Martín, Roson, Maria Ines, Toblli, Jorge Eduardo   +7 more
core   +1 more source

Hypertension: Renin-Angiotensin-Aldosterone System Alterations [PDF]

, 2015
Blockers of the renin-angiotensin-aldosterone system (RAAS), that is, renin inhibitors, angiotensin (Ang)-converting enzyme (ACE) inhibitors, Ang II type 1 receptor antagonists, and mineralocorticoid receptor antagonists, are a cornerstone in the ...
Danser, A.H.J. (Jan), Esch, J.H.M. (Joep) van, Meiracker, A.H. (Anton) van den, Riet, L. (Luuk) te, Roks, A.J.M. (Anton)   +4 more
core   +1 more source

Individualized Angiotensin‐Converting Enzyme (ACE)‐Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model [PDF]

, 2016
Patients with stable coronary artery disease (CAD) constitute a heterogeneous group in which the treatment benefits by angiotensin-converting enzyme (ACE)-inhibitor therapy vary between individuals.
Akkerhuis, KM, Bertrand, ME, Boersma, E, Brugts, JJ, Danser, AHJ, De Maat, M, Ferrari, R, Fox, KM, Oemrawsingh, RM, PERGENE investigators, Redekop, WK, Remme, WJ, Rudez, G, Simoons, ML, Van Vark, LC   +14 more
core   +1 more source